$AGIO
AGIOS PHARMACEUTICALS, INC.

2020 Q2 Form 10-Q Financial Statement

#000143922220000059 Filed on July 30, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $37.35M $26.22M
YoY Change 42.43% -35.12%
Cost Of Revenue $675.0K $303.0K
YoY Change 122.77%
Gross Profit $36.67M $25.92M
YoY Change 41.49% -35.87%
Gross Profit Margin 98.19% 98.84%
Selling, General & Admin $35.95M $32.39M
YoY Change 10.99% 21.63%
% of Gross Profit 98.03% 124.97%
Research & Development $54.09M $107.4M
YoY Change -49.64% 23.82%
% of Gross Profit 147.49% 414.34%
Depreciation & Amortization $2.400M $2.000M
YoY Change 20.0% 11.11%
% of Gross Profit 6.54% 7.72%
Operating Expenses $54.09M $140.1M
YoY Change -61.39% 23.57%
Operating Profit -$83.26M -$113.9M
YoY Change -26.87% 56.08%
Interest Expense $1.770M $3.990M
YoY Change -55.64% -5.0%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$81.50M -$109.9M
YoY Change -25.83% 59.81%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$90.48M -$109.9M
YoY Change -17.65% 59.82%
Net Earnings / Revenue -242.26% -419.02%
Basic Earnings Per Share -$1.31
Diluted Earnings Per Share -$1.31 -$1.871M
COMMON SHARES
Basic Shares Outstanding 68.96M shares 58.71M shares
Diluted Shares Outstanding 68.96M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $790.1M $495.4M
YoY Change 59.49% -30.9%
Cash & Equivalents $295.9M $83.58M
Short-Term Investments $494.3M $411.8M
Other Short-Term Assets $27.00M $19.10M
YoY Change 41.36% 23.23%
Inventory $11.23M $4.659M
Prepaid Expenses
Receivables $13.70M $9.800M
Other Receivables $4.300M $4.800M
Total Short-Term Assets $846.4M $533.7M
YoY Change 58.58% -29.2%
LONG-TERM ASSETS
Property, Plant & Equipment $33.93M $23.02M
YoY Change 47.4% -4.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.300M $128.6M
YoY Change -96.66% -41.47%
Other Assets $1.575M $0.00
YoY Change -100.0%
Total Long-Term Assets $129.8M $250.2M
YoY Change -48.12% 2.34%
TOTAL ASSETS
Total Short-Term Assets $846.4M $533.7M
Total Long-Term Assets $129.8M $250.2M
Total Assets $976.1M $783.9M
YoY Change 24.53% -21.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.46M $15.44M
YoY Change 0.17% -10.88%
Accrued Expenses $41.91M $49.22M
YoY Change -14.85% 90.82%
Deferred Revenue $0.00 $18.45M
YoY Change -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K
YoY Change
Total Short-Term Liabilities $64.35M $89.50M
YoY Change -28.1% 5.46%
LONG-TERM LIABILITIES
Long-Term Debt $500.0K $0.00
YoY Change
Other Long-Term Liabilities $352.8M $161.7M
YoY Change 118.18% 79.27%
Total Long-Term Liabilities $353.3M $161.7M
YoY Change 118.49% 79.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $64.35M $89.50M
Total Long-Term Liabilities $353.3M $161.7M
Total Liabilities $417.7M $251.2M
YoY Change 66.28% 43.46%
SHAREHOLDERS EQUITY
Retained Earnings -$1.647B -$1.308B
YoY Change 25.95% 42.41%
Common Stock $2.204B $1.840B
YoY Change 19.78% 5.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $558.5M $532.7M
YoY Change
Total Liabilities & Shareholders Equity $976.1M $783.9M
YoY Change 24.53% -21.47%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$90.48M -$109.9M
YoY Change -17.65% 59.82%
Depreciation, Depletion And Amortization $2.400M $2.000M
YoY Change 20.0% 11.11%
Cash From Operating Activities -$67.80M -$88.10M
YoY Change -23.04% 30.71%
INVESTING ACTIVITIES
Capital Expenditures -$4.200M -$1.300M
YoY Change 223.08% -7.14%
Acquisitions
YoY Change
Other Investing Activities $26.70M $65.70M
YoY Change -59.36% -169.23%
Cash From Investing Activities $22.50M $64.40M
YoY Change -65.06% -166.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 252.1M 3.800M
YoY Change 6534.21% -60.0%
NET CHANGE
Cash From Operating Activities -67.80M -88.10M
Cash From Investing Activities 22.50M 64.40M
Cash From Financing Activities 252.1M 3.800M
Net Change In Cash 206.8M -19.90M
YoY Change -1139.2% -87.09%
FREE CASH FLOW
Cash From Operating Activities -$67.80M -$88.10M
Capital Expenditures -$4.200M -$1.300M
Free Cash Flow -$63.60M -$86.80M
YoY Change -26.73% 31.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001439222
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36014
dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0662915
dei Entity Address Address Line1
EntityAddressAddressLine1
88 Sidney Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
649-8600
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.001 per share
dei Trading Symbol
TradingSymbol
AGIO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
69110084 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
295858000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80931000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
494270000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
483946000 USD
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
12023000 USD
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8952000 USD
CY2020Q2 agio Collaboration Receivable Duefrom Related Parties Current
CollaborationReceivableDuefromRelatedPartiesCurrent
2537000 USD
CY2019Q4 agio Collaboration Receivable Duefrom Related Parties Current
CollaborationReceivableDuefromRelatedPartiesCurrent
1539000 USD
CY2020Q2 agio Collaboration Receivable Other Current
CollaborationReceivableOtherCurrent
1827000 USD
CY2019Q4 agio Collaboration Receivable Other Current
CollaborationReceivableOtherCurrent
1928000 USD
CY2020Q2 agio Royalty Receivable Duefrom Related Parties Current
RoyaltyReceivableDuefromRelatedPartiesCurrent
1650000 USD
CY2019Q4 agio Royalty Receivable Duefrom Related Parties Current
RoyaltyReceivableDuefromRelatedPartiesCurrent
2900000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
11231000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
7331000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
26959000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24177000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
846355000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
611704000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4285000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
152929000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
89208000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
93643000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33925000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31472000 USD
CY2020Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
793000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
993000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1575000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2020Q2 us-gaap Assets
Assets
976141000 USD
CY2019Q4 us-gaap Assets
Assets
890741000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
15461000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
21896000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41911000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53142000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10933000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6672000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6642000 USD
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
309000 USD
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
273000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
64353000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
92886000 USD
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
50580000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
101874000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106074000 USD
CY2020Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
491000 USD
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
673000 USD
CY2020Q2 agio Sale Of Future Revenue Liability Noncurrent
SaleOfFutureRevenueLiabilityNoncurrent
250958000 USD
CY2019Q4 agio Sale Of Future Revenue Liability Noncurrent
SaleOfFutureRevenueLiabilityNoncurrent
0 USD
CY2020Q2 us-gaap Liabilities
Liabilities
417676000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
250213000 USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69058696 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69058696 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68401105 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68401105 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
69000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
68000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2203599000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2156363000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1636000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
202000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1646839000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1516105000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
558465000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
640528000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
976141000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
890741000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37347000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26221000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
124445000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56448000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
675000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
303000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1208000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
637000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90917000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107389000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
182173000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
202974000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35951000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32390000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
74452000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
64181000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
127543000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
140082000 USD
us-gaap Costs And Expenses
CostsAndExpenses
257833000 USD
us-gaap Costs And Expenses
CostsAndExpenses
267792000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-90196000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-113861000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-133388000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-211344000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1769000 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3990000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
4705000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
8395000 USD
CY2020Q2 agio Interest Expense Non Cash Sale Of Future Revenue
InterestExpenseNonCashSaleOfFutureRevenue
2051000 USD
CY2019Q2 agio Interest Expense Non Cash Sale Of Future Revenue
InterestExpenseNonCashSaleOfFutureRevenue
0 USD
agio Interest Expense Non Cash Sale Of Future Revenue
InterestExpenseNonCashSaleOfFutureRevenue
2051000 USD
agio Interest Expense Non Cash Sale Of Future Revenue
InterestExpenseNonCashSaleOfFutureRevenue
0 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-90478000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-109871000 USD
us-gaap Net Income Loss
NetIncomeLoss
-130734000 USD
us-gaap Net Income Loss
NetIncomeLoss
-202949000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.87
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.90
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.46
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68958091 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58722244 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68784109 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58589167 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-90478000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-109871000 USD
us-gaap Net Income Loss
NetIncomeLoss
-130734000 USD
us-gaap Net Income Loss
NetIncomeLoss
-202949000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1562000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
974000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1434000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2661000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88916000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108897000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129300000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-200288000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
640528000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5465000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19690000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-128000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-40256000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
625299000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1652000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20430000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1562000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-90478000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
558465000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
687537000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6003000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18108000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1687000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-93078000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
620257000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2770000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18547000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
974000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-109871000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
532677000 USD
us-gaap Net Income Loss
NetIncomeLoss
-130734000 USD
us-gaap Net Income Loss
NetIncomeLoss
-202949000 USD
us-gaap Depreciation
Depreciation
4906000 USD
us-gaap Depreciation
Depreciation
4042000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
40120000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
36655000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-473000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2019000 USD
agio Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
4435000 USD
agio Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
4208000 USD
agio Interest Expense Non Cash Sale Of Future Revenue
InterestExpenseNonCashSaleOfFutureRevenue
2051000 USD
agio Interest Expense Non Cash Sale Of Future Revenue
InterestExpenseNonCashSaleOfFutureRevenue
0 USD
agio Royalty Revenue Non Cash
RoyaltyRevenueNonCash
1650000 USD
agio Royalty Revenue Non Cash
RoyaltyRevenueNonCash
0 USD
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
3071000 USD
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
2071000 USD
agio Increase Decreasein Collaboration Receivable Duefrom Related Parties Current
IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent
998000 USD
agio Increase Decreasein Collaboration Receivable Duefrom Related Parties Current
IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent
62000 USD
agio Increase Decreasein Collaboration Receivable Other Current
IncreaseDecreaseinCollaborationReceivableOtherCurrent
-101000 USD
agio Increase Decreasein Collaboration Receivable Other Current
IncreaseDecreaseinCollaborationReceivableOtherCurrent
1552000 USD
agio Increase Decreasein Royalty Receivable Duefrom Related Parties Current
IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent
-1250000 USD
agio Increase Decreasein Royalty Receivable Duefrom Related Parties Current
IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent
466000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3900000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3790000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4357000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2517000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7524000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1874000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-8595000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7071000 USD
agio Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-61513000 USD
agio Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-22449000 USD
agio Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4149000 USD
agio Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3649000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-173155000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-191422000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
189601000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
144231000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
328883000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
343372000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8688000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3309000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
130594000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
195832000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
166000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7117000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8668000 USD
agio Proceeds From Sale Of Future Revenues Net Of Issuance Costs
ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts
250537000 USD
agio Proceeds From Sale Of Future Revenues Net Of Issuance Costs
ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
257488000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8668000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
214927000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13078000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80931000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70502000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295858000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83580000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3621000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
535000 USD
agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
0 USD
agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
112000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
42856000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2020Q2 agio Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold
ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold
255000000.0 USD
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
794400000 USD
CY2020Q2 agio Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold
ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold
255000000.0 USD
CY2020Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
496910000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1706000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
61000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
498555000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
636673000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
470000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
268000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
636875000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
28 security
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
113 security
CY2020Q2 us-gaap Inventory Net
InventoryNet
11231000 USD
CY2019Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
129700000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
345700000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 security
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1329000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
180000 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
8679000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6808000 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1223000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
343000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
7331000 USD
CY2020Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P8Y
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3800000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
7600000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
3500000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
7400000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3800000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
6800000 USD
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
3200000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
6300000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5886000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14380000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16773000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
18126000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
18660000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
19507000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
44385000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
137717000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
29171000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
108546000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M12D
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12897000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
18982000 USD
CY2020Q2 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
18697000 USD
CY2019Q4 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
21777000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4393000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8335000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5924000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4048000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41911000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53142000 USD
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
694000 USD
agio Contract With Customer Rebate Reserve Recoveries In Prior Years
ContractWithCustomerRebateReserveRecoveriesInPriorYears
677000 USD
agio Contract With Customer Right To Recover Product Prior Year Recoveries
ContractWithCustomerRightToRecoverProductPriorYearRecoveries
0 USD
agio Contract With Customer Prior Years Reserve Recoveries
ContractWithCustomerPriorYearsReserveRecoveries
1330000 USD
CY2020Q2 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
1218000 USD
CY2020Q2 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
3313000 USD
CY2020Q2 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
2048000 USD
CY2020Q2 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
6579000 USD
CY2019Q4 agio Contract With Customer Contractual Adjustment Reserve
ContractWithCustomerContractualAdjustmentReserve
874000 USD
CY2019Q4 agio Contract With Customer Rebate Reserve
ContractWithCustomerRebateReserve
1124000 USD
CY2019Q4 agio Contract With Customer Right To Recover Product Reserve
ContractWithCustomerRightToRecoverProductReserve
1798000 USD
CY2019Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
3796000 USD
agio Current Year Provision For Contractual Adjustments
CurrentYearProvisionForContractualAdjustments
6522000 USD
agio Current Year Provisions For Rebate Reserve
CurrentYearProvisionsForRebateReserve
4266000 USD
agio Provision For Right To Recover Product In Current Year
ProvisionForRightToRecoverProductInCurrentYear
726000 USD
agio Contract With Customer Current Year Reserve Provisions
ContractWithCustomerCurrentYearReserveProvisions
11514000 USD
agio Prior Year Provision For Contractual Adjustments
PriorYearProvisionForContractualAdjustments
-3000 USD
agio Prior Year Provisions For Rebate Reserve
PriorYearProvisionsForRebateReserve
22000 USD
agio Provision For Right To Recover Product In Prior Years
ProvisionForRightToRecoverProductInPriorYears
-476000 USD
agio Contract With Customer Prior Years Reserve Provisions
ContractWithCustomerPriorYearsReserveProvisions
-457000 USD
agio Contract With Customer Contract Adjustment Recoveries Current Year
ContractWithCustomerContractAdjustmentRecoveriesCurrentYear
5522000 USD
agio Contract With Customer Rebate Reserve Recoveries In Current Year
ContractWithCustomerRebateReserveRecoveriesInCurrentYear
1422000 USD
agio Contract With Customer Right To Recover Product Current Year Recoveries
ContractWithCustomerRightToRecoverProductCurrentYearRecoveries
0 USD
agio Contract With Customer Current Year Reserve Recoveries
ContractWithCustomerCurrentYearReserveRecoveries
6944000 USD
agio Contract With Customer Contract Adjustment Recoveries Prior Year
ContractWithCustomerContractAdjustmentRecoveriesPriorYear
653000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
540000 USD
CY2020Q2 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
5885000 USD
CY2019Q4 agio Contract With Customer Allowance And Reserves Liability
ContractWithCustomerAllowanceAndReservesLiability
3256000 USD
CY2020Q2 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
6579000 USD
CY2019Q4 agio Contract With Customer Total Allowances And Reserves
ContractWithCustomerTotalAllowancesAndReserves
3796000 USD
CY2019Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
8952000 USD
agio Contractwith Customer Asset Revenue Recognized
ContractwithCustomerAssetRevenueRecognized
61312000 USD
agio Contract With Customer Asset Proceeds From Collection Of Receivables
ContractWithCustomerAssetProceedsFromCollectionOfReceivables
58241000 USD
CY2020Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
12023000 USD
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4748000 USD
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
8009000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
61513000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
24419000 USD
CY2020Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
CY2019Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
5200000 USD
agio Revenue From Contracts With Customers Milestone Revenue Recognized
RevenueFromContractsWithCustomersMilestoneRevenueRecognized
0 USD
CY2019Q2 agio Revenue From Contracts With Customers Milestone Revenue Recognized
RevenueFromContractsWithCustomersMilestoneRevenueRecognized
0 USD
agio Revenue From Contracts With Customers Milestone Revenue Recognized
RevenueFromContractsWithCustomersMilestoneRevenueRecognized
0 USD
CY2020Q2 agio Revenue From Contracts With Customers Milestone Revenue Recognized
RevenueFromContractsWithCustomersMilestoneRevenueRecognized
0 USD
CY2020Q2 agio Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Estimated Effective Interest Rate
PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate
0.164
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6201485 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
922820 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
50.09
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
284814 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
18.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
241540 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
70.26
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6597951 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.72
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3927185 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
61.05
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6597951 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
58.72
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20430000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18547000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40120000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36655000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20430000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18547000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40120000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36655000 USD
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7898356 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7898356 shares
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7113868 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7113868 shares

Files In Submission

Name View Source Status
0001439222-20-000059-index-headers.html Edgar Link pending
0001439222-20-000059-index.html Edgar Link pending
0001439222-20-000059.txt Edgar Link pending
0001439222-20-000059-xbrl.zip Edgar Link pending
a102agiosroyaltypharma.htm Edgar Link pending
agio-20200630.htm Edgar Link pending
agio-20200630.xsd Edgar Link pending
agio-20200630_cal.xml Edgar Link unprocessable
agio-20200630_def.xml Edgar Link unprocessable
agio-20200630_htm.xml Edgar Link completed
agio-20200630_lab.xml Edgar Link unprocessable
agio-20200630_pre.xml Edgar Link unprocessable
exhibit31-1x06x30x20.htm Edgar Link pending
exhibit31-2x06x30x20.htm Edgar Link pending
exhibit32-1x06x30x20.htm Edgar Link pending
exhibit32-2x06x30x20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending